Alder BioPharmaceuticals, Inc. (ALDR) Given Buy Rating at Mizuho
Mizuho reiterated their buy rating on shares of Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) in a research report report published on Friday morning. Mizuho currently has a $32.00 price target on the biopharmaceutical company’s stock.
“We received an email from Alder yesterday on its recap of the 18th Congress of the International Headache Society (IHC) meeting as it relates to eptinezumab. What we found as incremental data points are Alder’s interviews with practicing physicians on the advantages of eptinezumab. We believe the IV formulation for eptinezumab is a positive differentiation from other CGRP products in late stage development because of its reimbursement and potentially better compliance.”,” the firm’s analyst commented.
Other equities analysts also recently issued reports about the stock. Needham & Company LLC restated a buy rating and set a $36.00 price objective on shares of Alder BioPharmaceuticals in a research note on Friday, June 9th. Leerink Swann restated an outperform rating and set a $32.00 price objective on shares of Alder BioPharmaceuticals in a research note on Monday, June 12th. BidaskClub upgraded shares of Alder BioPharmaceuticals from a strong sell rating to a sell rating in a research note on Friday, August 25th. Credit Suisse Group set a $11.00 price objective on shares of Alder BioPharmaceuticals and gave the stock a hold rating in a research note on Thursday, August 24th. Finally, Royal Bank Of Canada began coverage on shares of Alder BioPharmaceuticals in a research note on Thursday. They set an outperform rating and a $17.00 price objective for the company. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. The stock has an average rating of Hold and an average price target of $30.62.
Alder BioPharmaceuticals (ALDR) traded up 2.51% during trading on Friday, reaching $10.20. The company’s stock had a trading volume of 6,546,066 shares. The company’s market cap is $690.67 million. The company’s 50 day moving average price is $9.66 and its 200 day moving average price is $16.05. Alder BioPharmaceuticals has a 52 week low of $8.60 and a 52 week high of $35.62.
Alder BioPharmaceuticals (NASDAQ:ALDR) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.67) by $0.19. The business had revenue of $0.68 million for the quarter. During the same period last year, the company posted ($0.79) EPS. Alder BioPharmaceuticals’s revenue was up 518.2% on a year-over-year basis. On average, equities analysts anticipate that Alder BioPharmaceuticals will post ($5.74) earnings per share for the current fiscal year.
WARNING: “Alder BioPharmaceuticals, Inc. (ALDR) Given Buy Rating at Mizuho” was published by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/09/16/alder-biopharmaceuticals-inc-aldr-given-buy-rating-at-mizuho.html.
In other news, Director Stephen M. Dow bought 25,000 shares of the company’s stock in a transaction dated Tuesday, July 18th. The shares were bought at an average cost of $10.00 per share, with a total value of $250,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 10.60% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. Legal & General Group Plc raised its holdings in Alder BioPharmaceuticals by 2.6% in the 2nd quarter. Legal & General Group Plc now owns 15,496 shares of the biopharmaceutical company’s stock valued at $177,000 after acquiring an additional 400 shares during the period. The Manufacturers Life Insurance Company raised its holdings in Alder BioPharmaceuticals by 1.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 37,488 shares of the biopharmaceutical company’s stock valued at $430,000 after acquiring an additional 698 shares during the period. Teachers Advisors LLC raised its holdings in Alder BioPharmaceuticals by 1.5% in the 4th quarter. Teachers Advisors LLC now owns 76,809 shares of the biopharmaceutical company’s stock valued at $1,598,000 after acquiring an additional 1,171 shares during the period. Baird Financial Group Inc. raised its holdings in Alder BioPharmaceuticals by 7.9% in the 1st quarter. Baird Financial Group Inc. now owns 18,441 shares of the biopharmaceutical company’s stock valued at $384,000 after acquiring an additional 1,349 shares during the period. Finally, Swiss National Bank raised its holdings in Alder BioPharmaceuticals by 2.6% in the 1st quarter. Swiss National Bank now owns 66,342 shares of the biopharmaceutical company’s stock valued at $1,380,000 after acquiring an additional 1,700 shares during the period. 76.16% of the stock is currently owned by hedge funds and other institutional investors.
Alder BioPharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.